AN ECONOMIC EVALUATION OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) AFTER PRIOR CHEMOTHERAPY IN CHINAVALUE IN HEALTHIF62019-05-010OAAI
ECONOMIC EVALUATION OF ALK MUTATION TEST BY FISH AND VENTANA IHC TO GUIDE TARGETED TREATMENT IN CHINESE NSCLC PATIENTSVALUE IN HEALTHIF62018-09-010OAAI
ECONOMIC ANALYSIS OF ALK RELATED COMPANION DIAGNOSIS METHODS BEFORE THE TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCERVALUE IN HEALTHIF62017-10-010OAAI
PHARMACOECONOMICS ANALYSIS OF ACEI AND ARB AGAINST ESSENTIAL HYPERTENSION: A CASE STUDY OF SHANGHAIVALUE IN HEALTHIF62016-11-010OAAI
ESTIMATING THE VALUE OF A PATIENT ASSISTANCE PROGRAM FOR PEMETREXED AS A MAINTENANCE THERAPY FOR NSCLC IN CHINAVALUE IN HEALTHIF62016-05-010PREAI
REAL-WORLD DIAGNOSIS AND TREATMENT PATTERNS OF IRON DEFICIENCY ANEMIA IN CHINAVALUE IN HEALTHIF62012-11-010OAAI
THE IMPLEMENTATION OF ESSENTIAL MEDICINE POLICY IN CHINA: PROS AND CONSVALUE IN HEALTHIF62012-11-011OAAI